Dopamine efflux in the rat striatum evoked by electrical stimulation of the subthalamic nucleus: potential mechanism of action in Parkinson's disease.
The precise mechanism whereby continuous high-frequency electrical stimulation of the subthalamic nucleus ameliorates motor symptoms of Parkinson's disease is unknown. We examined the effects of high-frequency stimulation of regions dorsal to and within the subthalamic nucleus on dopamine efflux in the striatum of urethane-anaesthetized rats using constant potential amperometry. Complementary extracellular electrophysiological studies determined the activity of subthalamic nucleus neurons in response to similar electrical stimulation of the subthalamic nucleus. High-frequency stimulation of the subthalamic nucleus increased action potential firing in the subthalamic nucleus only during the initial stimulation period and was followed by a cessation of firing over the remainder of stimulation. Electrical stimulation of the subthalamic nucleus with 15 pulses elicited stimulus-time-locked increases in striatal dopamine efflux with maximal peak effects occurring at 50 Hz frequency and 300 microA intensity. Extended subthalamic nucleus stimulation (1000 pulses at 50 Hz; 300 microA) elicited a similar peak increase in striatal dopamine efflux that was followed by a relatively lower steady-state elevation in extracellular dopamine over the course of stimulation. In contrast, extended stimulation immediately adjacent and dorsal to the subthalamic nucleus resulted in an 11-fold greater increase in dopamine efflux that remained elevated over the course of the stimulation. Immunohistochemical staining for tyrosine hydroxylase revealed catecholaminergic fibers running immediately dorsal to and through the subthalamic nucleus. Taken together, these results suggest that enhanced dopamine release within the basal ganglia may be an important mechanism whereby high-frequency stimulation of the subthalamic nucleus improves motor symptoms of Parkinson's disease.
Lee
Kendall H
KH
Section of Neurosurgery, Dartmouth-Hitchcock Medical School, Lebanon, New Hampshire, 03756, USA.
Blaha
Charles D
CD
Harris
Brent T
BT
Cooper
Shannon
S
Hitti
Frederick L
FL
Leiter
James C
JC
Roberts
David W
DW
Kim
Uhnoh
U
D000200:Action Potentials / Q000502:physiology / Q000528:radiation effects; D000818:Animals; D001522:Behavior, Animal; D003342:Corpus Striatum / Q000378:metabolism* / Q000528:radiation effects; D003891:Desipramine / Q000494:pharmacology; D004195:Disease Models, Animal; D004298:Dopamine / Q000378:metabolism*; D018765:Dopamine Uptake Inhibitors / Q000494:pharmacology; D004307:Dose-Response Relationship, Radiation; D004347:Drug Interactions; D004558:Electric Stimulation / Q000379:methods*; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005260:Female; D005473:Fluoxetine / Q000494:pharmacology; D007150:Immunohistochemistry / Q000379:methods; D066298:In Vitro Techniques; D008297:Male; D009627:Nomifensine / Q000494:pharmacology; D010300:Parkinson Disease / Q000503:physiopathology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D017208:Rats, Wistar; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology; D020531:Subthalamic Nucleus / Q000528:radiation effects*; D014446:Tyrosine 3-Monooxygenase / Q000378:metabolism
D003891:Desipramine; D004298:Dopamine; D018765:Dopamine Uptake Inhibitors; D004791:Enzyme Inhibitors; D005473:Fluoxetine; D009627:Nomifensine; D017367:Selective Serotonin Reuptake Inhibitors; D014446:Tyrosine 3-Monooxygenase